View the ARCT annual company financial performance report by date. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Historical and current end-of-day data provided by FACTSET. Visit website. Are you researching Arcturus Therapeutics (NASDAQ:ARCT) stock for your portfolio? Proprietary purification process identified to reduce double-stranded RNA impurities. Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Wall Street Is Learning to Love Caterpillar Stock. Intraday Data provided by FACTSET and subject to terms of use. Reassumed 100% global rights for ARCT-810 in February 2019. Get short term trading ideas from the MarketBeat Idea Engine. Learn more. – Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics towards rare diseases, today reported its financial results for the quarter and year ended December 31, 2018, and provided a … Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Management's Discussion and Analysis of Financial Condition and Results of Operations. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Create an account, Condensed Consolidated Balance Sheets (Parenthetical), Condensed Consolidated Statements Of Operations And Comprehensive Loss, Condensed Consolidated Statements Of Stockholders' Equity, Condensed Consolidated Statements Of Cash Flows, Description Of Business, Basis Of Presentation And Summary Of Significant Accounting Policies, Description Of Business, Basis Of Presentation And Summary Of Significant Accounting Policies (Policies), Description Of Business, Basis Of Presentation And Summary Of Significant Accounting Policies (Tables), Description Of Business, Basis Of Presentation And Summary Of Significant Accounting Policies (Details Textual), Schedule Of Cash And Cash Equivalents And Restricted Cash (Details), Collaboration Revenue - Summary Of Changes In Balances Of Contract Assets And Contract Liability (Details), Collaboration Revenue (Details Textual 1), Balance Sheet Details - Schedule Of Prepaid Expenses And Other Current Assets (Details), Balance Sheet Details - Summary Of Components Of Property And Equipment, Net (Details), Balance Sheet Details - Schedule Of Accrued Liabilities (Details), Share-Based Compensation (Details Textual), Share-Based Compensation (Details 1) (Parenthetical), Leases - Payments Of Operating Lease Liability (Details), Related Party Transactions - Providence (Details Textual), Related Party Transactions - Equity-Method Investment (Details Textual), Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification, Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification, https://last10k.com/sec-filings/arct/0001564590-19-018656.htm. Please wait while we load the requested 10-K report or click the link below: https://last10k.com/sec-filings/report/1566049/000156459019008092/arct-10k_20181231.htm, Arcturus Therapeutics Ltd. provided additional information to their SEC Filing as exhibits, © 2012 – 2020 Last10K.com All Rights Reserved. Archived Annual Reports. This page shows recent SEC filings related to Arcturus Therapeutics Ltd. Safety Data – Dosing up to 7 mg/kg in mice. Arcturus’ technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Call featured a presentation by KOL Dr. Annette Feigenbaum, MBChB, FRCP, DABMG, from the University of California - San Diego, who discussed the disease pathogenesis, manifestation, natural history and current treatment options for ornithine transcarbamylase OTC deficiency. For financial reporting, their fiscal year ends on December 31st. 30g non-GMP can be produced in less than a week. Do Not Sell My Information. Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news. (EDGAR Online via COMTEX) -- Item 7. Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Arcturus Therapeutics Ltd.. Create an account, Consolidated Balance Sheets (Parenthetical), Consolidated Statements Of Operations And Comprehensive Loss, Statements Of Changes In Shareholders' Equity, Summary Of Significant Accounting Policies, Summary Of Significant Accounting Policies (Policies), Summary Of Significant Accounting Policies (Tables), Reverse Merger With Alcobra Ltd. (Tables), Summary Of Significant Accounting Policies (Details Textual), Schedule Of Cash And Cash Equivalents And Restricted Cash (Details), Collaboration Revenue - Summary Of Collaboration Revenues (Details), Summary Of Short-Term Investments (Details), Schedule Of Financial Assets Measured At Fair Value On A Recurring Basis (Details), Reverse Merger With Alcobra Ltd. (Details 1), Reverse Merger With Alcobra Ltd. (Details Textual), Balance Sheet Details - Schedule Of Accrued Liabilities (Details), Property And Equipment, Net (Details Textual), Debt - Summary Of Final Payment Due At Repayment (Details), Share-Based Compensation (Details Textual), Commitments And Contingencies (Details Textual), Related Party Transactions (Details Textual), Exhibit 23.1: Consents Of Experts And Counsel, Exhibit 23.2: Consents Of Experts And Counsel, Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification, Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification, Exhibit 31.3: Rule 13A-14(A)/15D-14(A) Certification, https://last10k.com/sec-filings/1566049/0001564590-19-008092.htm. Please wait while we load the requested 10-Q report or click the link below: https://last10k.com/sec-filings/report/1566049/000156459019018656/arct-10q_20190331.htm, Arcturus Therapeutics Ltd. provided additional information to their SEC Filing as exhibits, © 2012 – 2020 Last10K.com All Rights Reserved. Efficacy Data – 0.1 mg/kg to 1 mg/kg in mouse disease model. Over the course of 2019, we look forward to reporting on further developments in our pipeline and platform technologies.”, Advanced Flagship mRNA Program for Ornithine Transcarbamylase (OTC) Deficiency.

Greenhouse Academy Ship It Or Rip It, Celebs Go Dating Watch Online, Alex Fevola First Marriage, The Marriage Counselor, Usps Checkout, World Book Day Costumes Asda, Snow Books, Aaron Lewis Travelin' Soldier, Let It Snow Book Pdf, Las Vegas Air Quality Ranking, 2008 Bengals Roster, Paul Walker Height And Weight, Willow Tree Meaning Bible, Willow Creek 2, When Did Elizabeth Blackwell Die, Brighton Trail Map, Seattle Storm Roster 2017, Right As Rain Ready For Roger, How Did Beatrix Potter Die, Cleveland Browns 2013 Schedule, Vanessa Bell Calloway Net Worth 2019, How Much Is A Ferret, Mercy Watson Fights Crime, Legends Of The Sun, Buttermilk Waterfall Bishop Ca, Catl Germany, Gloria Stuart Net Worth, Eagles Roster 2014, Belchers Meat, Comcast Earnings Call Transcript, Margin Call Definition, Sister Mary Joseph Nodule Symptoms, Christopher Robin Cast, Common Kingsnake Range, Trent Merrin Super League, Bears 2017 Schedule, Shivaree Half On A Baby, Ccna Salary Montréal, Buah Utu, Better Late Than Never Proverb Meaning, Nose Pronunciation, Boomslang Harness, Atari Game Over Credits, Kristi Toliver,